Cash-rich pharma firms look set for a buying spree, as favorable biotech valuations and patent expirations incentivize dealmaking

At its core, the smart city is about people and improving the quality of our everyday lives.

Despite the absence of megadeals, M&A in the sector climbed from 2020 levels thanks in part to strong PE and SPAC activity

Heightened interest in medical suppliers, contract research organizations and biotech firms resulted in an impressive year for healthcare dealmaking.

The value of healthcare M&A in H1 surpassed pre-pandemic levels

Increasing cooperation between global PE players is pushing up price tags  

New challenges may lie ahead for the pharmaceutical industry

Dealmaking within the PMB sector enjoyed an impressive start as companies across the globe embarked on their post-pandemic recovery.  

Companies seeking mergers can expect scrutiny and litigation

M&A value in the healthcare sector (incorporating pharma, medical and biotech) stayed relatively robust in 2020, even without the kind of blockbuster deals the sector had become accustomed to seeing in recent years

The TMT sector was buoyed by global spikes in demand as the world shifted toward virtual interactions in every walk of life